JAK1 and psoriasis: A case series of concomitant psoriasis and AD, successfully treated with Upadacitinib, demonstrated that JAK1 inhibition was of benefit in cases with clinical overlap between these two conditions, with all patients achieving complete remission of both diseases with no adverse events seen after at least 32 weeks of follow-up.10